SARS-CoV-2 mutations and their viral variants
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
2022Yazar
Coşar, BegümKaragülleoğlu, Zeynep Yağmur
Ünal, Sinan
İnce, Ahmet Turan
Uncuoğlu, Dilruba Beyza
Tuncer, Gizem
Kılınç, Buğrahan Regaip
Özkan, Yunus Emre
Özkoç, Hikmet Ceyda
Demir, İbrahim Naki
Eker, Ali
Karagöz, Feyzanur
Şimsek, Said Yasin
Yaşar, Bünyamin
Pala, Mehmetcan
Demir, Ayşegül
Atak, İrem Naz
Mendi, Ayşegül Hanife
Bengi, Vehdi Umut
Sevel, Güldane Cengiz
Altuntaş, Evrim Güneş
Kılıç, Pelin
Demir Dora, Devrim
Üst veri
Tüm öğe kaydını gösterÖzet
Mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occur spontaneously during
replication. Thousands of mutations have accumulated and continue to since the emergence of the virus. As novel
mutations continue appearing at the scene, naturally, new variants are increasingly observed.
Since the first occurrence of the SARS-CoV-2 infection, a wide variety of drug compounds affecting the binding
sites of the virus have begun to be studied. As the drug and vaccine trials are continuing, it is of utmost
importance to take into consideration the SARS-CoV-2 mutations and their respective frequencies since these
data could lead the way to multi-drug combinations. The lack of effective therapeutic and preventive strategies
against human coronaviruses (hCoVs) necessitates research that is of interest to the clinical applications.
The reason why the mutations in glycoprotein S lead to vaccine escape is related to the location of the mutation and the affinity of the protein. At the same time, it can be said that variations should occur in areas such as
the receptor-binding domain (RBD), and vaccines and antiviral drugs should be formulated by targeting more
than one viral protein.